How many Clazakizumab clinical trials are there?

11 Clazakizumab clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 7 are marked completed.

Are Clazakizumab clinical trials recruiting in 2026?

No active Clazakizumab trials are recruiting on ClinicalTrials.gov as of the current AACT refresh. Trials may resume; this page is updated daily.

What conditions is Clazakizumab being studied for?

Clazakizumab is being studied for Antibody-mediated Rejection, COVID-19, Transplant Glomerulopathy, Kidney Transplant; Complications, Frailty and 11 more. The trials are grouped by indication on this page.

What phase is Clazakizumab in?

Clazakizumab clinical trials span 1 Phase 3, 8 Phase 2. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.

Who sponsors Clazakizumab clinical trials?

The lead sponsor across the most Clazakizumab trials is CSL Behring, with 8 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Clazakizumab Clinical Trials (2026): 11 Studies for Antibody-mediated Rejection & COVID-19

Creator: Hipa.ai Research
Published: 2026-05-12T16:54:52.170Z

Hipa.ai Research · Source: ClinicalTrials.gov / AACT

Synced daily from ClinicalTrials.gov via AACT. Last sync: June 12, 2026.

11 Clazakizumab clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 7 indications (including Antibody-mediated Rejection & COVID-19) and 1,622 total planned enrollment. 1 Phase 3 Clazakizumab trial and 8 Phase 2 are listed. Most recent activity: NCT05727384 (May 2026).

Clazakizumab clinical trials at a glance: phase × recruitment status

Phase	active not recruiting	completed	terminated	unknown	Total
P1/P2	1	1			2
P2		6	1	1	8
P3			1		1

Clazakizumab clinical trials by indication

COVID-19 (3)

NCT	Acronym	Phase	Status	Title
NCT04381052	—	P2	terminated	Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection
NCT04343989	—	P2	completed	A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection
NCT04348500	IL-6	P2	completed	Clazakizumab (Anti-Interleukin 6 (IL-6) Monoclonal) Compared to Placebo for Coronavirus Disease 2019 (COVID-19)

Antibody-mediated Rejection (3)

NCT	Acronym	Phase	Status	Title
NCT03380377	—	P1/P2	completed	Clazakizumab for Chronic and Active Antibody Mediated Rejection Post-Kidney Transplant
NCT03744910	IMAGINE	P3	terminated	Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients
NCT03444103	—	P2	completed	A Pilot Trial of Clazakizumab in Late ABMR

Inflammation (1)

NCT	Acronym	Phase	Status	Title
NCT05727384	RIGHT	P2	completed	Improving Physical Function in Older Adults Using an Anti-inflammation Drug: The RIGHT Study

COVID-19 Infection (1)

NCT	Acronym	Phase	Status	Title
NCT04494724	—	P2	unknown	Clazakizumab vs. Placebo - COVID-19 Infection

Asthma (1)

NCT	Acronym	Phase	Status	Title
NCT04129931	—	P2	completed	PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study

Kidney Failure, Chronic (1)

NCT	Acronym	Phase	Status	Title
NCT03380962	—	P1/P2	active not recruiting	Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant

Rheumatoid Arthritis (1)

NCT	Acronym	Phase	Status	Title
NCT02015520	—	P2	completed	Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis

Clazakizumab pivotal trial highlights (Phase 2/3/4)

Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.

Acronym	NCT	Phase	Status	Indication	Enrollment	PubMed
IMAGINE	NCT03744910	P3	terminated	Antibody-mediated Rejection	194	PMID 36550562
RIGHT	NCT05727384	P2	completed	Inflammation	29	PMID 41518612
IL-6	NCT04348500	P2	completed	COVID-19	17	—

Terminated and withdrawn Clazakizumab trials (2)

Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.

NCT03744910terminatedClazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients
NCT04381052terminatedStudy for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection

All Clazakizumab trials (11)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

NCT ID	Acronym	Title	Phase	Status	Enrollment	Sponsor	Started
NCT05727384	RIGHT	Improving Physical Function in Older Adults Using an Anti-inflammation Drug: The RIGHT Study	P2	completed	29	Anne B. Newman	Aug 2023
NCT03380962		Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant	P1/P2	active not recruiting	20	Stanley Jordan, MD	Feb 2018
NCT04129931		PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study	P2	completed	950	University of North Carolina, Chapel Hill	Dec 2019
NCT03380377		Clazakizumab for Chronic and Active Antibody Mediated Rejection Post-Kidney Transplant	P1/P2	completed	10	Stanley Jordan, MD	Feb 2018
NCT03744910	IMAGINE	Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients	P3	terminated	194	CSL Behring	Oct 2019
NCT04494724		Clazakizumab vs. Placebo - COVID-19 Infection	P2	unknown	60	The Methodist Hospital Research Institute	Jul 2020
NCT04381052		Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection	P2	terminated	1	Columbia University	May 2020
NCT04343989		A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection	P2	completed	178	NYU Langone Health	Mar 2020
NCT04348500	IL-6	Clazakizumab (Anti-Interleukin 6 (IL-6) Monoclonal) Compared to Placebo for Coronavirus Disease 2019 (COVID-19)	P2	completed	17	Cedars-Sinai Medical Center	Apr 2020
NCT03444103		A Pilot Trial of Clazakizumab in Late ABMR	P2	completed	20	Medical University of Vienna	Jan 2018
NCT02015520		Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis	P2	completed	143	CSL Behring	Jun 2012

Clazakizumab clinical trials: frequently asked questions

How many Clazakizumab clinical trials are there?: 11 Clazakizumab clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 7 are marked completed.
Are Clazakizumab clinical trials recruiting in 2026?: No active Clazakizumab trials are recruiting on ClinicalTrials.gov as of the current AACT refresh. Trials may resume; this page is updated daily.
What conditions is Clazakizumab being studied for?: Clazakizumab is being studied for Antibody-mediated Rejection, COVID-19, Transplant Glomerulopathy, Kidney Transplant; Complications, Frailty and 11 more. The trials are grouped by indication on this page.
What phase is Clazakizumab in?: Clazakizumab clinical trials span 1 Phase 3, 8 Phase 2. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors Clazakizumab clinical trials?: The lead sponsor across the most Clazakizumab trials is CSL Behring, with 8 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Clazakizumabas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed June 12, 2026.

Related pages on Hipa.ai:

Clazakizumab overview Clazakizumab evidence & publications